Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
The event is expected to feature thought leaders discussing celiac disease drug development led by
|Event:||Innovate KOL Panel|
|Date:||Monday, June 4, 2018|
|Time:||10:00am-11:00am (Eastern Time)|
|Location:||Marriott Marquis – Dogwood Room (Mezzanine Level)|
|901 Massachusetts Ave NW, Washington, D.C. 20001|
Management expects to be in attendance for one-on-one meetings with the scientific community and other interested parties from
Innovate intends to make available a live webcast and subsequent replay of the event on its website. To access the webcast, please visit the tab in the Events and Presentations section of Innovate’s investor relations website.
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in
In celiac disease, larazotide is the only drug which has successfully met the primary endpoint with statistical significance in a Phase 2b efficacy clinical trial (342 patients). Innovate successfully completed the End of Phase 2 Meeting with the
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to our operations and business strategy. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, the success, timing and cost of our drug development program and our ongoing or future clinical trials, the lengthy and unpredictable nature of the drug approval process, and our ability to commercialize our product candidates if approved. These risks and uncertainties include, but may not be limited to, those described in our Annual Report on Form 10-K filed with the
Source: Innovate Biopharmaceuticals, Inc